AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Effect on Weight Loss of Exenatide Versus Placebo
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 196
- Registration Number
- NCT00375492
- Locations
- 🇺🇸
Research Site, Renton, Washington, United States
A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2006-09-12
- Last Posted Date
- 2015-05-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 156
- Registration Number
- NCT00374907
- Locations
- 🇺🇸
Diabetes & Glandular Disease Research Assoc,, Inc., San Antonio, Texas, United States
🇺🇸Va San Diego Healthcare System, San Diego, California, United States
🇺🇸Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 70
- Registration Number
- NCT00372944
- Locations
- 🇷🇴
Research Site, Cluj-Napoca, Romania
Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT00372853
- Locations
- 🇺🇸
Research Site, Memphis, Tennessee, United States
AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 88
- Registration Number
- NCT00372788
- Locations
- 🇷🇴
Research Site, Cluj-Napoca, Romania
A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 843
- Registration Number
- NCT00363896
- Locations
- 🇫🇷
Almirall Investigational Sites#669, Montpellier,cedex 5, France
🇩🇰Almirall Investigational Sites#397, Odense C., Denmark
🇩🇪Almirall Investigational Sites#757, Jena, Germany
A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 235
- Registration Number
- NCT00360334
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes
- First Posted Date
- 2006-08-03
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 377
- Registration Number
- NCT00359879
- Locations
- 🇲🇽
Research Site, San Luis Potosi, Mexico
Exenatide Versus Glimepiride in Patients With Type 2 Diabetes
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2015-09-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1029
- Registration Number
- NCT00359762
- Locations
- 🇬🇧
Research Site, Wiltshire, United Kingdom
Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-07-31
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 804
- Registration Number
- NCT00358436
- Locations
- 🇺🇸
Almirall Investigational Sites#930, Los Angeles, California, United States
🇺🇸Almirall Investigational Sites#922, Los Angeles, California, United States
🇺🇸Almirall Investigational Sites#902, Riverside, California, United States